Placebo to bevacizumab — Competitive Intelligence Brief

Placebo to bevacizumab (Placebo to bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor. Area: Oncology.

phase 3 VEGF inhibitor VEGF-A Oncology Small molecule

Target snapshot

Placebo to bevacizumab (Placebo to bevacizumab) — Hoffmann-La Roche. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to bevacizumab TARGET	Placebo to bevacizumab	Hoffmann-La Roche	phase 3	VEGF inhibitor	VEGF-A
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Ranibizumab (Lucentis)	Ranibizumab (Lucentis)	Greater Houston Retina Research	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)
Syfovre™	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor class)

1. Hoffmann-La Roche · 2 drugs in this class
2. Genentech, Inc. · 1 drug in this class
3. Genzyme, a Sanofi Company · 1 drug in this class
4. Innostellar Biotherapeutics Co.,Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Eli Lilly and Company · 1 drug in this class
8. Seoul National University Bundang Hospital · 1 drug in this class